Mechanistic study of antisense long non-coding RNA STEAP3-AS1 in breast cancer

Abstract

Aim: This study aims to investigate the expression and function of antisense long non-coding RNA (lncRNA) STEAP3-AS1 in breast cancer (BC). Additionally, it explores STEAP3’s regulatory relationship withSTEAP3-AS1 and potential signaling pathways to provide a theoretical foundation for identifying novel therapeutic targets.

Methods: Database prediction and collection of tissue samples were employed alongside a cell proliferation assay and Transwell migration and invasion assay to examine STEAP3-AS1 expression levels in BC tissues and cell lines, as well as its impact on cellular functions. Statistical analyses were performed, including two-tailed Student’s t-test, Mann-Whitney U test and analysis of variance (ANOVA).

Results: Both database and 9 paired clinical tissue sample results demonstrate that STEAP3-AS1 expression was significantly downregulated in BC compared with normal breast tissues P < 0.05). Compared with the estrogen receptor/progesterone receptor (ERPR)-negative (–)/human epidermal growth factor receptor-2 (Her2)-positive (+) subtype, the ERPR(+)/Her2(−) and ERPR(−)/Her2(−) subtypes exhibited a significantly lower expression level of STEAP3-AS1 P < 0.05). Overexpression of STEAP3-AS1 markedly suppressed the proliferation, migration, and invasion capabilities of MDA-MB-231 and MCF-7 cells compared with negative controls P < 0.05). Furthermore, STEAP3-AS1 exhibited a positive synergistic effect with its sense strand STEAP3, inhibiting BC cell migration and invasion.

Conclusions: This study is the first to demonstrate the tumor-suppressive role of STEAP3-AS1 in BC. These findings provide novel insights into the mechanisms underlying BC progression and offer critical theoretical support for the development of new therapeutic strategies.

Keywords

breast cancer / STEAP3-AS1 / STEAP3 / tumor suppressor / cuproptosis

References

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.

[2] McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical Diagnosis and Management of Breast Cancer. J Nucl Med. 2016; 57 Suppl 1: 9S-16S.

[3] De Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence. Nutrients. 2019; 11: 1514.

[4] Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020; 60: 14-27.

[5] Balawardena J, Skandarajah T, Rathnayake W, Joseph N. Breast Cancer Survival in Sri Lanka. JCO Glob Oncol. 2020; 6: 589-99.

[6] Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019; 177: 237-50.

[7] Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. Prog Mol Biol Transl Sci. 2017; 151: 1-32.

[8] Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015; 313: 165-73.

[9] Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019; 321: 288-300.

[10] Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018; 24: 511-20.

[11] Pinker K, Chin J, Melsaether AN, Morris EA, Moy L. Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment. Radiology. 2018; 287: 732-47.

[12] Greenwalt I, Zaza N, Das S, Li BD. Precision Medicine and Targeted Therapies in Breast Cancer. Surg Oncol Clin N Am. 2020; 29: 51-62.

[13] Yan J, Liu Z, Du S, Li J, Ma L, Li L. Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era. Methods Mol Biol. 2020; 2204: 53-61.

[14] St Laurent G, Wahlestedt C, Kapranov P. The Landscape of long noncoding RNA classification. Trends Genet. 2015; 31: 239-51.

[15] Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021; 65: 625-39.

[16] Wang YQ, Jiang DM, Hu SS, Zhao L, Wang L, Yang MH, et al. SATB2-AS1 Suppresses Colorectal Carcinoma Aggressiveness by Inhibiting SATB2-Dependent Snail Transcription and Epithelial-Mesenchymal Transition. Cancer Res. 2019; 79: 3542-56.

[17] Luo H, Zhu G, Xu J, Lai Q, Yan B, Guo Y, et al. HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. Cancer Cell. 2019; 36: 645-59.e8.

[18] Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al.; Cancer Genome Atlas Research Network; Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 2018; 33: 706-20.e9.

[19] Olivero CE, Martínez-Terroba E, Zimmer J, Liao C, Tesfaye E, Hooshdaran N, et al. p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis. Mol Cell. 2020; 77: 761-74.e8.

[20] Semenza GL. The Genomics and Genetics of Oxygen Homeostasis. Annu Rev Genomics Hum Genet. 2020; 21: 183-204.

[21] Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15: 2675-86.

[22] Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16: 1466-71.

[23] Shih JW, Kung HJ. Long non-coding RNA and tumor hypoxia: new players ushered toward an old arena. J Biomed Sci. 2017; 24: 53.

[24] Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022; 132: e159839.

[25] Chang YN, Zhang K, Hu ZM, Qi HX, Shi ZM, Han XH, et al. Hypoxia-regulated lncRNAs in cancer. Gene. 2016; 575: 1-8.

[26] Choudhry H, Harris AL, McIntyre A. The tumour hypoxia induced non-coding transcriptome. Mol Aspects Med. 2016; 47-48: 35-53.

[27] Dong J, Xu J, Wang X, Jin B. Influence of the interaction between long noncoding RNAs and hypoxia on tumorigenesis. Tumour Biol. 2016; 37: 1379-85.

[28] Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. The interplay between HIF-1α and noncoding RNAs in cancer. J Exp Clin Cancer Res. 2020; 39: 27.

[29] Wang X, Zhao D, Xie H, Hu Y. Interplay of long non-coding RNAs and HIF-1α: A new dimension to understanding hypoxia-regulated tumor growth and metastasis. Cancer Lett. 2021; 499: 49-59.

[30] Zhou L, Jiang J, Huang Z, Jin P, Peng L, Luo M, et al. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m⁶A-mediated degradation of STEAP3 mRNA. Mol Cancer. 2022; 21: 168.

[31] Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, et al. TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. Cancer Res. 2015; 75: 3728-37.

[32] Zheng Y, Xu Q, Liu M, Hu H, Xie Y, Zuo Z, et al. lnCAR: A Comprehensive Resource for lncRNAs from Cancer Arrays. Cancer Res. 2019; 79: 2076-83.

[33] Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25: 25-9.

[34] Gene Ontology Consortium; Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023; 224: iyad031.

[35] Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023; 51: D638-46.

[36] Peng R, Zheng M, Kang H, Dong Y, Wang P, Wang C, et al. Methyl-CpG-binding domain 2 mitigates osteoarthritis through Steap3 promoter methylation and chondrocyte ferroptosis regulation. Exp Mol Med. 2025; 57: 2629-42.

[37] Sun Y, Liu J, Xiao K, Chen S, Ma J, Cao M, et al. STEAP3-SLC39A8-mediated microglia ferroptosis involved in neurotoxicity in rats after exposure to lead and cadmium combined. Int Immunopharmacol. 2025; 146: 113854.

[38] D’Alessandro A, Keele GR, Hay A, Nemkov T, Earley EJ, Stephenson D, et al. Ferroptosis regulates hemolysis in stored murine and human red blood cells. Blood. 2025; 145: 765-83.

[39] Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 2008; 15: 1723-33.

[40] Wu J, Yang Y, He Y, Li Q, Wang X, Sun C, et al. EFTUD2 gene deficiency disrupts osteoblast maturation and inhibits chondrocyte differentiation via activation of the p53 signaling pathway. Hum Genomics. 2019; 13: 63.

[41] Wu L, Tian X, Zuo H, Zheng W, Li X, Yuan M, et al. miR-124-3p delivered by exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells inhibits ferroptosis to attenuate ischemia-reperfusion injury in steatotic grafts. J Nanobiotechnology. 2022; 20: 196.

[42] Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 2025; 53: D672-7.

[43] Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28: 27-30.

[44] Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019; 28: 1947-51.

[45] Latgé G, Poulet C, Bours V, Josse C, Jerusalem G. Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers. Int J Mol Sci. 2018; 19: 123.

[46] Jiang T, Zhu J, Jiang S, Chen Z, Xu P, Gong R, et al. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy. Adv Sci (Weinh). 2023; 10: e2207257.

[47] Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, et al. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016; 7: 12791.

[48] Min L, Chen L, Huang D, Zhang Y, You A, Yan X, et al. LncRNA HIF1A-AS2 promotes triple-negative breast cancer progression and paclitaxel resistance via MRPS23 protein. Heliyon. 2024; 10: e36469.

[49] Liu W, Ma J, Cheng Y, Zhang H, Luo W, Zhang H. HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells. Breast Cancer (Dove Med Press). 2016; 8: 223-9.

[50] Sun L, Li Y, Yang B. Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53’s transcriptional activity. Biochem Biophys Res Commun. 2016; 478: 323-9.

[51] Zheng F, Chen J, Zhang X, Wang Z, Chen J, Lin X, et al. The HIF-1α antisense long non-coding RNA drives a positive feedback loop of HIF-1α mediated transactivation and glycolysis. Nat Commun. 2021; 12: 1341.

[52] Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, et al.; RIKEN Genome Exploration Research Group; Genome Science Group (Genome Network Project Core Group); FANTOM Consortium. Antisense transcription in the mammalian transcriptome. Science. 2005; 309: 1564-6.

[53] Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022; 82: 2252-66.

[54] Vance KW, Ponting CP. Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet. 2014; 30: 348-55.

[55] Villegas VE, Zaphiropoulos PG. Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci. 2015; 16: 3251-66.

[56] Su WY, Li JT, Cui Y, Hong J, Du W, Wang YC, et al. Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer. Cell Res. 2012; 22: 1374-89.

[57] Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev. 2010; 24: 2264-9.

[58] Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012; 491: 454-7.

[59] Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, et al. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008; 14: 723-30.

[60] Halley P, Kadakkuzha BM, Faghihi MA, Magistri M, Zeier Z, Khorkova O, et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 2014; 6: 222-30.

[61] Villegas VE, Rahman MF, Fernandez-Barrena MG, Diao Y, Liapi E, Sonkoly E, et al. Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1. Mol Oncol. 2014; 8: 912-26.

[62] Changchit N, Laokulrath N, Rushatamukayanunt P, Pisarnturakit P. Is the ≥1 cm Width of the Resection Margin in Benign and Borderline Phyllodes Tumor Necessary to Reduce Recurrence? Breast J. 2024; 2024: 1432313.

[63] Wen B, Mousadoust D, Warburton R, Pao JS, Dingee C, Chen L, et al. Phyllodes tumours of the breast: Outcomes and recurrence after excision. Am J Surg. 2020; 219: 790-4.

[64] Moo TA, Alabdulkareem H, Tam A, Fontanet C, Lu Y, Landers A, et al. Association Between Recurrence and Re-Excision for Close and Positive Margins Versus Observation in Patients with Benign Phyllodes Tumors. Ann Surg Oncol. 2017; 24: 3088-92.

[65] Humaran D, Castillo A, Blay L, Pascual I, Matute-Molina K, Pérez-Anker J, et al. Towards a New Standard: Prospective Validation of Ex Vivo Fusion Confocal Microscopy for Intraoperative Margin Assessment in Breast-Conserving Cancer Surgery. Cancers (Basel). 2025; 17: 3848.